Zentalis Pharmaceuticals, Inc. Common Stock
ZNTLZentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancers with high unmet medical needs. The company's approach involves designing small molecule therapeutics that inhibit cancer-driving proteins, with a focus on oncology indications such as solid tumors and hematologic malignancies.
Company News
The oncology landscape is experiencing rapid regulatory advancement as precision medicine and genomics expand significantly. Multiple biotech companies are advancing cancer therapies toward accelerated FDA approvals in 2026, with the precision medicine market projected to grow from $138.67 billion in 2026 to $537.17 billion by 2035. Key developme...
Incyclix Bio, a cell cycle control company, appointed Dr. Kimberly Blackwell to its Board of Directors. Dr. Blackwell brings over 20 years of drug development experience and expertise in oncology research, particularly in breast cancer treatment.
Zentalis Pharmaceuticals granted non-qualified stock options to purchase 381,000 shares of common stock to six newly hired employees under their 2022 Employment Inducement Incentive Award Plan.
Zentalis Pharmaceuticals reported a narrower net loss in Q2 2025, reducing operating expenses by 44.7% while maintaining cash reserves to support operations through late 2027. The company continues developing azenosertib, a cancer therapy, with ongoing clinical trials for platinum-resistant ovarian cancer.
Zentalis Pharmaceuticals granted 14,000 stock options to a newly hired employee under its 2022 Employment Inducement Incentive Award Plan, with options vesting over four years at an exercise price of $1.19 per share.